Literature DB >> 27261908

Classification and Pathology of Lung Cancer.

Min Zheng1.   

Abstract

Advancement in the understanding of lung tumor biology enables continued refinement of lung cancer classification, reflected in the recently introduced 2015 World Health Organization classification of lung cancer. In small biopsy or cytology specimens, special emphasis is placed on separating adenocarcinomas from the other lung cancers to effectively select tumors for targeted molecular testing. In resection specimens, adenocarcinomas are further classified based on architectural pattern to delineate tissue types of prognostic significance. Neuroendocrine tumors are divided into typical carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma based on a combination of features, especially tumor cell proliferation rate.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Classification; Immunohistochemistry; Lung cancer; Molecular testing; Pathology

Mesh:

Year:  2016        PMID: 27261908     DOI: 10.1016/j.soc.2016.02.003

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  73 in total

1.  ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.

Authors:  Vivek Shukla; Mahadev Rao; Hongen Zhang; Jeanette Beers; Darawalee Wangsa; Danny Wangsa; Floryne O Buishand; Yonghong Wang; Zhiya Yu; Holly S Stevenson; Emily S Reardon; Kaitlin C McLoughlin; Andrew S Kaufman; Eden C Payabyab; Julie A Hong; Mary Zhang; Sean Davis; Daniel Edelman; Guokai Chen; Markku M Miettinen; Nicholas P Restifo; Thomas Ried; Paul A Meltzer; David S Schrump
Journal:  Cancer Res       Date:  2017-09-21       Impact factor: 12.701

2.  The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.

Authors:  Sarmishtha De; Elise G Holvey-Bates; Kala Mahen; Belinda Willard; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 11.205

3.  Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature.

Authors:  Xiangjun Qi; Guoming Chen; Zhuangzhong Chen; Jing Li; Wenmin Chen; Jietao Lin; Lizhu Lin
Journal:  Int J Gen Med       Date:  2021-08-11

4.  Increased miR-21a provides metabolic advantages through suppression of FBP1 expression in non-small cell lung cancer cells.

Authors:  Qingchun Dai; Na Li; Xiaohong Zhou
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

5.  Reduced circulating exosomal miR-382 predicts unfavorable outcome in non-small cell lung cancer.

Authors:  Rong Luo; Hong Liu; Jing Chen
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

Review 6.  Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence?

Authors:  J Palussière; M Cazayus; S Cousin; M Cabart; F Chomy; V Catena; X Buy
Journal:  Curr Oncol Rep       Date:  2021-05-05       Impact factor: 5.075

7.  Association of ERBB4 genetic polymorphism with the risk and prognosis of non-small cell lung cancer in Chinese Han population: A population-based case-control study.

Authors:  Wan-Ping Wang; Hai-Bo Bian; Xia-Zhen Wang; Liang Liu; Ding Wei
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

8.  Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma.

Authors:  Zaiyan Wang; Xiaoning Li; Hao Chen; Li Han; Xiaobin Ji; Qiubo Wang; Li Wei; Yafang Miao; Jing Wang; Jianfeng Mao; Zeming Zhang
Journal:  Med Sci Monit       Date:  2021-05-12

9.  Prognostic impact according to the proportion of the lepidic subtype in stage IA acinar-predominant lung adenocarcinoma.

Authors:  Hyun Woo Jeon; Young-Du Kim; Sung Bo Sim; Mi Hyoung Moon
Journal:  Thorac Cancer       Date:  2021-05-25       Impact factor: 3.500

Review 10.  Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.

Authors:  Mohammad Mojtaba Sadeghi; Mohamed F Salama; Yusuf A Hannun
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.